Cargando…

Is VATS suitable for lung diseases with hemoptysis? Experience from a hemoptysis treatment center in China

BACKGROUND: Surgery is crucial in the treatment of the potentially fatal pulmonary hemoptysis condition. Currently, most patients with hemoptysis are treated by traditional open surgery (OS). To illustrate the effectiveness of video-assisted thoracic surgery (VATS) for hemoptysis, we developed a ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bing, Yao, Li, Sheng, Jian, Liu, Xiaoyu, Jiang, Yuhui, Shen, Lei, Xu, Feng, Dai, Xiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268410/
https://www.ncbi.nlm.nih.gov/pubmed/37316807
http://dx.doi.org/10.1186/s12890-023-02506-4
_version_ 1785059086371389440
author Wang, Bing
Yao, Li
Sheng, Jian
Liu, Xiaoyu
Jiang, Yuhui
Shen, Lei
Xu, Feng
Dai, Xiyong
author_facet Wang, Bing
Yao, Li
Sheng, Jian
Liu, Xiaoyu
Jiang, Yuhui
Shen, Lei
Xu, Feng
Dai, Xiyong
author_sort Wang, Bing
collection PubMed
description BACKGROUND: Surgery is crucial in the treatment of the potentially fatal pulmonary hemoptysis condition. Currently, most patients with hemoptysis are treated by traditional open surgery (OS). To illustrate the effectiveness of video-assisted thoracic surgery (VATS) for hemoptysis, we developed a retrospective study of surgical interventions for lung disease with hemoptysis. METHODS: We collected and then analysed the data, including general information and post-operative outcomes, from 102 patients who underwent surgery for a variety of lung diseases with hemoptysis in our hospital between December 2018 and June 2022. RESULTS: Sixty three cases underwent VATS and 39 cases underwent OS. 76.5% of patients were male (78/102). Comorbidities with diabetes and hypertension were 16.7% (17/102) and 15.7% (16/102) respectively. The diagnoses based on postoperative pathology included aspergilloma in 63 cases (61.8%), tuberculosis in 38 cases (37.4%) and bronchiectasis in 1 case (0.8%). 8 patients underwent wedge resection, 12 patients underwent segmentectomy, 73 patients underwent lobectomy and 9 patients underwent pneumonectomy. There were 23 cases of postoperative complications, of which 7 (30.4%) were in the VATS group, significantly fewer than 16 (69.6%) in the OS group (p = 0.001). The OS procedure was identified as the only independent risk factor for postoperative complications. The median (IQR) of postoperative drainage volume in the first 24 h was 400 (195–665) ml, which was 250 (130–500) ml of the VATS group, significantly less than the 550 (460–820) ml of the OS group (p < 0.05). The median (IQR) of pain scores 24 h after surgery was 5 (4–9). The median (IQR) of postoperative drainage tube removal time was 9.5 (6–17) days for all patients, and it was 7 (5–14) days for the VATS group, which was less than 15 (9–20) days for the OS group. CONCLUSION: VATS for patients with lung disease presenting with hemoptysis is an effective and safe option that may be preferred when the hemoptysis is uncomplicated and the patient's vital signs are stable.
format Online
Article
Text
id pubmed-10268410
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102684102023-06-15 Is VATS suitable for lung diseases with hemoptysis? Experience from a hemoptysis treatment center in China Wang, Bing Yao, Li Sheng, Jian Liu, Xiaoyu Jiang, Yuhui Shen, Lei Xu, Feng Dai, Xiyong BMC Pulm Med Research BACKGROUND: Surgery is crucial in the treatment of the potentially fatal pulmonary hemoptysis condition. Currently, most patients with hemoptysis are treated by traditional open surgery (OS). To illustrate the effectiveness of video-assisted thoracic surgery (VATS) for hemoptysis, we developed a retrospective study of surgical interventions for lung disease with hemoptysis. METHODS: We collected and then analysed the data, including general information and post-operative outcomes, from 102 patients who underwent surgery for a variety of lung diseases with hemoptysis in our hospital between December 2018 and June 2022. RESULTS: Sixty three cases underwent VATS and 39 cases underwent OS. 76.5% of patients were male (78/102). Comorbidities with diabetes and hypertension were 16.7% (17/102) and 15.7% (16/102) respectively. The diagnoses based on postoperative pathology included aspergilloma in 63 cases (61.8%), tuberculosis in 38 cases (37.4%) and bronchiectasis in 1 case (0.8%). 8 patients underwent wedge resection, 12 patients underwent segmentectomy, 73 patients underwent lobectomy and 9 patients underwent pneumonectomy. There were 23 cases of postoperative complications, of which 7 (30.4%) were in the VATS group, significantly fewer than 16 (69.6%) in the OS group (p = 0.001). The OS procedure was identified as the only independent risk factor for postoperative complications. The median (IQR) of postoperative drainage volume in the first 24 h was 400 (195–665) ml, which was 250 (130–500) ml of the VATS group, significantly less than the 550 (460–820) ml of the OS group (p < 0.05). The median (IQR) of pain scores 24 h after surgery was 5 (4–9). The median (IQR) of postoperative drainage tube removal time was 9.5 (6–17) days for all patients, and it was 7 (5–14) days for the VATS group, which was less than 15 (9–20) days for the OS group. CONCLUSION: VATS for patients with lung disease presenting with hemoptysis is an effective and safe option that may be preferred when the hemoptysis is uncomplicated and the patient's vital signs are stable. BioMed Central 2023-06-14 /pmc/articles/PMC10268410/ /pubmed/37316807 http://dx.doi.org/10.1186/s12890-023-02506-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Bing
Yao, Li
Sheng, Jian
Liu, Xiaoyu
Jiang, Yuhui
Shen, Lei
Xu, Feng
Dai, Xiyong
Is VATS suitable for lung diseases with hemoptysis? Experience from a hemoptysis treatment center in China
title Is VATS suitable for lung diseases with hemoptysis? Experience from a hemoptysis treatment center in China
title_full Is VATS suitable for lung diseases with hemoptysis? Experience from a hemoptysis treatment center in China
title_fullStr Is VATS suitable for lung diseases with hemoptysis? Experience from a hemoptysis treatment center in China
title_full_unstemmed Is VATS suitable for lung diseases with hemoptysis? Experience from a hemoptysis treatment center in China
title_short Is VATS suitable for lung diseases with hemoptysis? Experience from a hemoptysis treatment center in China
title_sort is vats suitable for lung diseases with hemoptysis? experience from a hemoptysis treatment center in china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268410/
https://www.ncbi.nlm.nih.gov/pubmed/37316807
http://dx.doi.org/10.1186/s12890-023-02506-4
work_keys_str_mv AT wangbing isvatssuitableforlungdiseaseswithhemoptysisexperiencefromahemoptysistreatmentcenterinchina
AT yaoli isvatssuitableforlungdiseaseswithhemoptysisexperiencefromahemoptysistreatmentcenterinchina
AT shengjian isvatssuitableforlungdiseaseswithhemoptysisexperiencefromahemoptysistreatmentcenterinchina
AT liuxiaoyu isvatssuitableforlungdiseaseswithhemoptysisexperiencefromahemoptysistreatmentcenterinchina
AT jiangyuhui isvatssuitableforlungdiseaseswithhemoptysisexperiencefromahemoptysistreatmentcenterinchina
AT shenlei isvatssuitableforlungdiseaseswithhemoptysisexperiencefromahemoptysistreatmentcenterinchina
AT xufeng isvatssuitableforlungdiseaseswithhemoptysisexperiencefromahemoptysistreatmentcenterinchina
AT daixiyong isvatssuitableforlungdiseaseswithhemoptysisexperiencefromahemoptysistreatmentcenterinchina